November 6 | 2019

2cureX fortsätter sitt arbete med att säkra ett starkt IP-skydd för sitt IndiTreat-test i USA

Read more
October 15 | 2019

2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong

Read more
October 15 | 2019

2cureX fortsätter sin IP-expansion genom säkrande av patent på sitt IndiTreat-test i Hong Kong

Read more
October 8 | 2019

2cureX har ingått avtal med ett av de största privata cancersjukhusen i Norden

Read more
October 8 | 2019

2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries

Read more
September 25 | 2019

2cureX Newsletter September 2019

Read more
September 25 | 2019

2cureX Newsletter September 2019

Read more
August 23 | 2019

2cureX offentliggör halvårsrapport för det första halvåret 2019

Read more
August 23 | 2019

2cureX publishes half-year report for the first half of 2019

Read more
July 23 | 2019

2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial

Read more
July 23 | 2019

2cureX meddelar att patienter framgångsrikt inkluderats i pankreascancerstudie med IndiTreat®

Read more
June 27 | 2019

Last day of trading in BTA 1 in 2cureX AB

Read more
June 27 | 2019

Sista dag för handel med BTA 1 i 2cureX AB

Read more
June 25 | 2019

Byte av Certified Adviser till Svensk Kapitalmarknadsgranskning AB

Read more
June 25 | 2019

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

Read more
June 20 | 2019

2cureX utser Dr. Henrik Harling till Chief Medical Officer

Read more
June 20 | 2019

2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer

Read more
May 28 | 2019

Communique from the Annual General Meeting in 2cureX AB (publ)

Read more